DarshanTalks Podcast

Send us Fan Mail

We discuss five key legal and regulatory considerations for a digital sales force:
Starting with updates to the Physician Payment Sunshine Act, emphasizing the need for training, robust internal controls, and monitoring.
 It also touches on guidance for interactions with healthcare professionals, emphasizing transparency and ethical practices.
 The SIUU guidance is discussed, emphasizing accurate and fair presentation of scientific information.
The updated CMS guidance recommends comprehensive compliance programs, promoting a culture of compliance and
Lastly, the DOJ pilot program for clawbacks in employment agreements is outlined, urging employers to review agreements, establish clear policies, and conduct due diligence.
Addressing these considerations ensures digital sales forces contribute to an ethical and responsible healthcare industry, requiring companies to stay updated and provide ongoing training.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

We explore the crucial aspects outlined by the FTC regarding comparative claims in drug and device advertising. 
the paramount importance of transparency in promotional efforts,
the pitfalls associated with broad generalizations, and 
the need for readiness in the face of scrutiny from both the FDA and the FTC.

Providing a valuable intersection of pharmacy, law, and marketing, our short offers a comprehensive guide for navigating the complex landscape of comparative claims in the healthcare industry. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this podcast, we explore a groundbreaking shift where clinical research is emerging as a viable care option, known as Clinical Research as a Care Option (CRACO). While the concept seems promising, particularly for patients with conditions like rare diseases or cancer, it introduces a host of concerns. The alignment of Institutional Review Board (IRB) goals with the essence of a clinical study becomes pivotal. If the trial's outcome is already known, it may be labeled a seeding trial, raising ethical and FDA-related red flags. Conversely, administering a drug with uncertain effectiveness to a hopeful patient brings its own set of ethical and legal challenges. 
This evolving landscape demands careful consideration and resolution of ethical and legal issues associated with integrating clinical research and care. 

Stay tuned as discussions on this innovative approach continue to unfold.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this podcast, we discuss artificial intelligence (AI) and machine learning, exploring their pivotal roles in drug development. AI, a fusion of computer science, statistics, and engineering, employs algorithms to perform tasks like learning, decision-making, and prediction. Within the context of drug development, we unravel three significant applications of AI. First, it aids in scanning medical literature for pertinent findings; second, it predicts individual responses to treatments and assesses side effect risks; and third, it enables the creation of digital twins for intervention modeling.

Join us as we navigate the potential of conversational agents and chatbots equipped with AI, serving as invaluable tools in clinical trial inquiries and adverse event reporting. Yet, the integration of AI comes with its own set of risks. As regulatory bodies like the FDA shift toward a risk-based analysis approach, it is crucial for stakeholders—whether practitioners, sites, sponsors, or research organizations—to remain vigilant and comprehend the evolving regulatory landscape. In this episode, we shed light on the impact and risks associated with AI in drug development, offering insights into navigating this transformative era.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The National Advertising Division (NAD) recently examined a TV ad by Bravecto, comparing its flea and tick prevention product with NexGard's. The ad suggested Bravecto's greater effectiveness, disputed by NexGard. NAD sided with NexGard, emphasizing the need for clear and conspicuous disclosures in comparative advertising.

 In a separate case, Google's ads for YouTube TV claimed a $600 cost savings over cable, leading to a dispute with a cable provider. NAD supported the cable provider, stressing the importance of clear definitions for comparable services to prevent consumer misinterpretation. 

These cases underscore the FTC's focus on addressing ambiguous and misleading comparative claims, particularly in drug product advertising—a realm already subject to FDA caution.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this podcast, five crucial considerations for obtaining approval for a digital speaker program are discussed:

1. Privacy Compliance:
   - Consider where audience data will be stored and ensure compliance with privacy laws (TCPA, CCPA, GDPR, etc.).
   - Prioritize secure handling of sensitive information and always obtain audience consent.

2. Transparency and Disclosure:
   - Adhere to FTC requirements for transparency and disclosure.
   - Communicate upfront about sponsorships, product claims, and any financial relationships impacting the content.

3. Controlled Audience Targeting:
   - Tailor the digital presentation to specific individuals or groups.
   - Adjust tone, scientific detail, and compliance messages based on the target audience (e.g., clinicians, P&T committees).

4. Distinguishing Marketing from Education:
   - Clearly differentiate between marketing and educational content.
   - Ensure that educational materials genuinely inform without serving solely as a sales pitch to benefit from legal protections.

5. Product or Health Claim Evaluation:
   - Scrutinize the presentation topic to determine if it constitutes a product claim or a disease awareness advertisement.
   - Adhere to FDA requirements for product claims, ensuring substantial evidence, while disease awareness ads follow a lower scientific evidence standard.

For assistance with digital engagement or marketing programs, contact Darshan Kulkarni at [email protected]

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

he recently issued FDA guidance mandates manufacturers, packers, and distributors to adhere to new standards, emphasizing mandatory product and facility registrations, creation of safety substantiation information, and implementation of adverse event reporting. Daron breaks down key definitions, clarifies information submission processes, and discusses public accessibility. 

Tune in to stay informed about the crucial expectations, including adverse event reporting, recordkeeping, and safety substantiation, to ensure compliance with the evolving regulatory landscape.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this podcast episode, we'll uncover five strategies to expedite the digital promotion review process. Starting with
1. Policy creation and training emphasizes aligning policies across platforms, incorporating key stakeholders' expectations, and ensuring consistency with relevant agreements and guidelines. 
2. Pre-review meetings with marketing teams help establish a shared perspective, streamlining the process.
3. AI-based tools offer preliminary data analysis, although current applications are somewhat basic. 
4. Modular approvals involve reviewing individual components before the final review, aiming to accelerate the overall process. 
5. Lastly, applying quality learnings from past programs aids in avoiding mistakes and optimizing the promotional review process. 

Tune in for more insights and tips!  

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Darshan Kulkarni delves into the recently released draft guidance by the Center for Devices and Radiological Health (CDRH) outlining best practices for selecting a predicate device when preparing a 510(k) submission. This guidance underscores four key considerations.

The draft guidance emphasizes the significance of technological characteristics. If the new device shares the same technological characteristics as the predicate device, the 510(k) summary should include a comprehensive summary of these features.

Design-related recalls take center stage in the FDA's recommendations. The agency discourages choosing a predicate device that has been subject to a design-related recall. If a submitter opts for such a device, they must explicitly address how they've mitigated the safety concerns that led to the recall.

Transparency and documentation constitute the third crucial consideration. The FDA stresses the need for a detailed 510(k) summary that provides a comprehensive understanding of the basis for determining substantial equivalence.

The guidance encourages the inclusion of a narrative explanation in the 510(k) summary. This narrative should elucidate the process behind selecting the predicate device, offering transparency and insight into the decision-making process.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Darshan Kulkarni discusses the FDA's IT strategy for 2024 to 2027. The FDA aims to create a unified FDA ecosystem, promote cross-functional collaboration, and foster a more integrated organizational culture. Key goals include 
strengthening IT infrastructure, 
modernizing enterprise services, and 
optimizing the IT services portfolio for stable, resilient, and adaptive solutions aligned with mission needs. 
The FDA emphasizes the importance of sharing data to drive efficiency, excellence, and public health innovation. Additionally, the strategy involves adopting artificial intelligence and staying proactive in identifying opportunities and risks related to emerging technologies.

Support the show

www.kulkarnilawfirm.com